Beeline debuted with $300 million in backing.
The company features a pipeline derived from Bristol Myers Squibb (BMS) assets.
BMS contributed 5 assets to Beeline's precision immunology-focused debut.
Announcement referenced from GlobeNewswire, dated around April 15, 2026.
Interests include Interleukin-2, BMS-986497, and BMS-986326.